In CML, high expression of EZH2 was associated with the activation of BCR-ABL, and EZH2 expression was promoted through the STAT5 signaling pathway, which decreased after treatment of CML stem cells with TKI [32, 33]. The gene discussed is EZH2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.